Urology
Volume 66, Issue 5 , Pages 1038-1042 , November 2005

Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages

  • Kevin S. Ross

      Affiliations

    • Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Harry A. Guess

      Affiliations

    • Department of Epidemiology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina
    • ,
  • H. Ballentine Carter

      Affiliations

    • Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland
    • Corresponding Author InformationReprint requests: H. Ballentine Carter, M.D., Department of Urology, 403 Marburg, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287-2101.

Received 28 August 2004 ,Accepted 12 May 2005.

References 

  1. Sirovich BE , Schwartz LM , Woloshin S . Screening men for prostate and colorectal cancer in the United States (does practice reflect the evidence?) . JAMA . 2003;289:1414–1420
  2. Etzioni R , Penson DF , Legler JM , et al.   Overdiagnosis due to prostate-specific antigen screening (lessons from U.S. prostate cancer incidence trends) . J Natl Cancer Inst . 2002;94:981–990
  3. Draisma G , Boer R , Otto SJ , et al.   Lead times and overdetection due to prostate-specific antigen screening (estimates from the European Randomized Study of Screening for Prostate Cancer) . J Natl Cancer Inst . 2003;95:868–878
  4. Lu-Yao G , Stukel TA , Yao SL . Prostate-specific antigen screening in elderly men . J Natl Cancer Inst . 2003;95:1792–1797
  5. Cooperberg MR , Grossfeld GD , Lubeck DP , et al.   National practice patterns and time trends in androgen ablation for localized prostate cancer . J Natl Cancer Inst . 2003;95:981–989
  6. Albertsen PC , Hanley JA , Gleason DF , et al.   Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer . JAMA . 1998;280:975–980
  7. Ross KS , Carter HB , Pearson JD , et al.   Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection . JAMA . 2000;284:1399–1404
  8. Available: at: www.census.gov. Accessed August 28, 2004.
  9. Holmberg L , Bill-Axelson A , Helgesen F , et al.   Scandinavian Prostatic Cancer Group Study Number 4 (a randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer) . N Engl J Med . 2002;347:781–789
  10. Tornblom M , Eriksson H , Franzen S , et al.   Lead time associated with screening for prostate cancer . Int J Cancer . 2004;108:122–129
  11. Available: at: www.cdc.gov/nchs/products/pubs/pubd/lftbls/lftbls.htm. Accessed August 28, 2004.
  12. McGregor M , Hanley JA , Boivin JF , et al.   Screening for prostate cancer (estimating the magnitude of overdetection) . Can Med Assoc J . 1998;159:1368–1372
  13. Schwartz KL , Alibhai SM , Tomlinson G , et al.   Continued undertreatment of older men with localized prostate cancer . Urology . 2003;62:860–865
  14. Schwartz LM , Woloshin S , Fowler FJ , et al.   Enthusiasm for cancer screening in the United States . JAMA . 2004;291:71–78

PII: S0090-4295(05)00754-5

doi: 10.1016/j.urology.2005.05.030

Urology
Volume 66, Issue 5 , Pages 1038-1042 , November 2005

Article Tools

* Image Usage & Resolution